GlycoMimetics, Inc. (GLYC) has an overall financial health rating of C+ with a composite score of 2 out of 5.
Component scores: Discounted Cash Flow (DCF): 4/5, Return on Equity (ROE): 1/5, Return on Assets (ROA): 1/5, Debt-to-Equity (D/E): 1/5, Price-to-Earnings (P/E): 1/5, Price-to-Book (P/B): 5/5.
This suggests the company faces some financial challenges worth monitoring. Rating as of 2025-07-02.
| Date | Rating | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-07-02 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 | |
| 2025-07-01 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 | |
| 2025-06-30 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 | |
| 2025-06-27 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 | |
| 2025-06-26 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 | |
| 2025-06-25 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 | |
| 2025-06-13 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 | |
| 2025-06-12 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 | |
| 2025-06-11 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 | |
| 2025-06-10 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 | |
| 2025-06-09 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 | |
| 2025-06-06 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
